{"id": "370504", "url": "https://fevir.net/resources/Composition/370504", "date": "2025-08-18T13:22:42.074Z", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/outcome-measure-report"], "versionId": "24", "lastUpdated": "2025-08-18T13:22:42.074Z"}, "type": {"text": "Outcome Measure Report", "coding": [{"code": "OutcomeMeasureReport", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "OutcomeMeasureReport"}]}, "title": "Outcome Measures Report for NCT03640312", "author": [{"display": "[No author listed.]"}], "status": "final", "custodian": {"type": "Organization", "display": "Computable Publishing LLC", "reference": "Organization/118079"}, "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "relatesTo": [{"type": "cite-as", "targetMarkdown": "Outcome Measures Report for NCT03640312 [Database Entry: FHIR Composition Resource]. Contributors: [No author listed.] [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 370504. Revised 2025-08-18. Available at: https://fevir.net/resources/Composition/370504. Computable resource at: https://fevir.net/resources/Composition/370504."}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "370504", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-outcome-measure-report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "resourceType": "Composition", "section": [{"focus": {"type": "EvidenceVariable", "display": "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367882", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-primaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Change in Mean Systolic Blood Pressure at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Change in Mean Systolic Blood Pressure at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367903", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-primaryOutcomeMeasure-0--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Change in Mean Systolic Blood Pressure at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367904", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-primaryOutcomeMeasure-0--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Change in Mean Systolic Blood Pressure at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367941", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-primaryOutcomeMeasure-0-OutcomeAnalysis-0-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367882", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-primaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Change in Mean Systolic Blood Pressure at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367883", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Systolic Blood Pressure at 6 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367905", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-0--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312", "reference": "Evidence/367906", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-0--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367942", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-0-OutcomeAnalysis-1-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367883", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367884", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Change in Mean Diastolic Blood Pressure at 6 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Change in Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367907", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-1--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Change in Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312", "reference": "Evidence/367908", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-1--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Change in Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367943", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-1-OutcomeAnalysis-2-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367884", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Change in Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367885", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Diastolic Blood Pressure at 6 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Mean Diastolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367909", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-2--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Diastolic Blood Pressure at 6 weeks for Candesartan in NCT03640312", "reference": "Evidence/367910", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-2--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Diastolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367944", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-2-OutcomeAnalysis-3-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367885", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Diastolic Blood Pressure at 6 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367886", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 and 12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367911", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks for Candesartan in NCT03640312", "reference": "Evidence/367912", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-3-6-weeks-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at  (NCT03640312)", "reference": "EvidenceVariable/370506", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-3-6-weeks-", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 6 weeks at  (NCT03640312)"}, {"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367913", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367914", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-3-12-weeks-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at  (NCT03640312)", "reference": "EvidenceVariable/370507", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-3-12-weeks-", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Proportion of Patients With Hypertension Control at 6 and 12 weeks - 12 weeks at  (NCT03640312)"}]}, {"code": {"text": "OutcomeAnalysisList", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367945", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-3-OutcomeAnalysis-4-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367886", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Outcome Analysis List for Proportion of Patients With Hypertension Control at 6 and 12 weeks (NCT03640312)"}]}, {"focus": {"type": "EvidenceVariable", "display": "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367887", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Number of Patients Requiring Step up Treatment at 6 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Number of Patients Requiring Step up Treatment at 6 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367915", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-4--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Number of Patients Requiring Step up Treatment at 6 weeks for Candesartan in NCT03640312", "reference": "Evidence/367916", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-4--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Number of Patients Requiring Step up Treatment at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367946", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-4-OutcomeAnalysis-5-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367887", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Number of Patients Requiring Step up Treatment at 6 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367888", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367917", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-5--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367918", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-5--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367947", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-5-OutcomeAnalysis-6-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367888", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Proportion of Patients With Adverse Event Free Hypertension Control at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Medication Adherence at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367889", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Medication Adherence at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Medication Adherence at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367919", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-6--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Medication Adherence at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367920", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-6--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Medication Adherence at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367948", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-6-OutcomeAnalysis-7-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Medication Adherence at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367889", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Medication Adherence at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Health-related Quality of Life at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367890", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-7", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Health-related Quality of Life at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Data are available on only 28 participants in the intervention group for the mental health T score.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for QUARTET LDQT in NCT03640312", "reference": "Evidence/367921", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) for Candesartan in NCT03640312", "reference": "Evidence/367922", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at  (NCT03640312)", "reference": "EvidenceVariable/370508", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-7-Change-in-Physical-Health-T-score--OPEN---PROMIS---CLOSE--", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Health-related Quality of Life at 12 weeks - Change in Physical Health T score (PROMIS) at  (NCT03640312)"}, {"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for QUARTET LDQT in NCT03640312", "reference": "Evidence/367923", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) for Candesartan in NCT03640312", "reference": "Evidence/367924", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at  (NCT03640312)", "reference": "EvidenceVariable/370509", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-7-Change-in-Mental-Health-T-score--OPEN---PROMIS---CLOSE--", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Health-related Quality of Life at 12 weeks - Change in Mental Health T score (PROMIS) at  (NCT03640312)"}]}, {"code": {"text": "OutcomeAnalysisList", "coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367949", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-8-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367950", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-9-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Health-related Quality of Life at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367890", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-7", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Outcome Analysis List for Health-related Quality of Life at 12 weeks (NCT03640312)"}]}, {"focus": {"type": "EvidenceVariable", "display": "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367891", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-8", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Change in Mean Systolic Blood Pressure at 6 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">6 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Change in Mean Systolic Blood Pressure at 6 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367925", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-8--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Change in Mean Systolic Blood Pressure at 6 weeks for Candesartan in NCT03640312", "reference": "Evidence/367926", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-8--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Change in Mean Systolic Blood Pressure at 6 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367951", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-8-OutcomeAnalysis-10-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)", "reference": "EvidenceVariable/367891", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-8", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Change in Mean Systolic Blood Pressure at 6 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367896", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367927", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-0--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367928", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-0--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367952", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-0-OutcomeAnalysis-11-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367896", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Percentage of Participants With Serious Adverse Events (SAEs) at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367897", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">All randomized participants</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367929", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-1--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367930", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-1--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367953", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-1-OutcomeAnalysis-12-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367897", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Percentage of Participants With Potentially Related Adverse Events at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367898", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Rate of Adverse Events of Special Interest at 12 weeks", "section": [{"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Rate of Adverse Events of Special Interest at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367931", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-2--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Rate of Adverse Events of Special Interest at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367932", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-2--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Rate of Adverse Events of Special Interest at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367954", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-2-OutcomeAnalysis-13-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367898", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Rate of Adverse Events of Special Interest at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Mean Change in Serum Potassium at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367899", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Serum Potassium at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Mean Change in Serum Potassium at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367933", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-3--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Serum Potassium at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367934", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-3--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Serum Potassium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367955", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-3-OutcomeAnalysis-14-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Mean Change in Serum Potassium at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367899", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Serum Potassium at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367900", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Serum Sodium at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Mean Change in Serum Sodium at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367935", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-4--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Serum Sodium at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367936", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-4--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Serum Sodium at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367956", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-4-OutcomeAnalysis-15-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367900", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Serum Sodium at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367901", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Blood Urea Nitrogen at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Mean Change in Blood Urea Nitrogen at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367937", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-5--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Blood Urea Nitrogen at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367938", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-5--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Blood Urea Nitrogen at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367957", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-5-OutcomeAnalysis-16-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367901", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-5", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Blood Urea Nitrogen at 12 weeks (NCT03640312)"}]}]}, {"focus": {"type": "EvidenceVariable", "display": "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367902", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Serum Creatinine at 12 weeks", "section": [{"code": {"text": "OutcomeMeasurePopulationDescription"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Modified intent to treat whereby all those participants with data at any follow-up time point and baseline to contribute to analyses will be included in analyses according to arm to which they were randomized, regardless of adherence to the study protocol.</div>", "status": "generated"}, "title": "Outcome Measure Population Description"}, {"code": {"text": "OutcomeMeasureReportingStatus"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Posted</div>", "status": "generated"}, "title": "Outcome Measure Reporting Status"}, {"code": {"text": "OutcomeMeasureTimeFrame"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">12 weeks</div>", "status": "generated"}, "title": "Outcome Measure Time Frame"}, {"code": {"text": "OutcomeGroupList"}, "title": "Outcome Group List", "section": [{"code": {"text": "OG000"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks."}], "title": "QUARTET LDQT"}, {"code": {"text": "OG001"}, "text": {"div": "<div xmlns=\"http://www.w3.org/1999/xhtml\">Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks.</div>", "status": "generated"}, "entry": [{"display": "Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}], "title": "Candesartan"}]}, {"code": {"text": "OutcomeClassList"}, "title": "Outcome Class List", "section": [{"code": {"coding": [{"code": "results", "system": "https://fevir.net/resources/CodeSystem/179423", "display": "Results"}]}, "entry": [{"type": "Evidence", "display": "Mean Change in Serum Creatinine at 12 weeks for QUARTET LDQT in NCT03640312", "reference": "Evidence/367939", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-6--OG000", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Serum Creatinine at 12 weeks for Candesartan in NCT03640312", "reference": "Evidence/367940", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-6--OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, {"type": "Evidence", "display": "Mean Change in Serum Creatinine at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "reference": "Evidence/367958", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcomeMeasure-6-OutcomeAnalysis-17-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "focus": {"type": "EvidenceVariable", "display": "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367902", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-otherOutcome-6", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "title": "Mean Change in Serum Creatinine at 12 weeks (NCT03640312)"}]}]}]}